MIR224: MIR224 is a microRNA that has been implicated in various biological processes and diseases. It has been shown to be up-regulated in siAQP4 treated animals, leading to a reduction in Cx43 expression [PMC5843607]. Estradiol (E2) is known to play a crucial role in the regulation of MIR224, and it has been identified as a key regulator of MIR224 in both esophageal adenocarcinoma (EA) and esophageal squamous cell carcinoma (ESCC) [PMC6609598]. In addition, MIR224 has been identified as a potential biomarker for EA [PMC6609598]. Aberrant expression of miRNAs, including MIR224, has also been observed in autoimmune diseases such as lupus erythematosus [PMC5351619]. MIR224 is one of the miRNAs involved in the progression of pancreatic adenocarcinoma (PAAD) [PMC6005310]. It also plays a critical role in chemoresistance in ovarian cancer cells by regulating the PRKCD pathway [PMC8071157]. Furthermore, MIR224 targets glycine methyltransferases and is involved in epithelial-mesenchymal transition (EMT) regulation in colorectal cancer [PMC9775527] [PMC5240405]. It has also been implicated as a prognostic candidate for colorectal cancer [PMC5935085]. Additionally, MIR224 is overexpressed in WNT medulloblastomas and promotes migration of hepatocellular carcinoma (HCC) and colorectal cancer (CRC) by binding to Smad4 and HOXD10 proteins [PMC4333163] [PMC5226496]. Furthermore, it regulates NCR1 expression levels and plays a role in post-stroke angiogenesis processes along with other miRNAs such as miR225, miR335, and miR139-5p [PMC9166526] [PMC6732937].